Novadaq Technologies Inc.

Novadaq Technologies Inc.

October 16, 2007 07:00 ET

Novadaq Launches PINPOINT: Company's First Minimally Invasive Imaging System

System Recommended by the College of Chest Physicians for Lung Cancer Treatment

TORONTO, ONTARIO--(Marketwire - Oct. 16, 2007) -

Attention Business Editors:

Novadaq® Technologies Inc. (TSX:NDQ), a developer of real-time medical imaging
systems and image guided therapies for the operating room, today announced that
it will launch the PINPOINT™ endoscopic imaging system at the Annual Meeting
of American College of Chest Physicians (ACCP), CHEST 2007, to be held in Chicago,
IL, October 22nd - 25th, 2007. PINPOINT is based upon the endoscopic technology
Novadaq acquired from Xillix Technologies Inc., and is designed to not only
perform white light bronchoscopy, but also the more clinically relevant imaging
commonly referred to as autofluorescence and narrow band imaging. Many studies
have shown autofluorescence to be more effective in the detection and localization
of central airway cancers than conventional white light bronchoscopy. The ACCP
Evidence Based Practice Guidelines now recommend the use of autofluorescence
bronchoscopy for the localization of certain lung cancers, for guiding endoluminal
therapies, and as a surveillance tool in patients with pre-invasive disease.

"Autofluorescence bronchoscopy has definitely enhanced my ability to
treat patients with lung cancer and I am glad to see that it is now being
recommended by the ACCP," said Patrick Ross, Jr., M.D., Ph.D., Associate
Professor and Director of Thoracic Surgery at Ohio State University and
Director of Thoracic Oncology at the Arthur G. James Cancer Hospital.
"Autofluorescence, compared to the gold standard white light bronchoscopy,
provides a more detailed assessment of the patient's anatomy before pulmonary
resection, a more accurate assessment for the presence of early lung cancers,
and the ability to more precisely perform endoluminal therapies such as Photo
Dynamic Therapy (PDT). Autofluorescence bronchoscopy has become firmly
incorporated as a standard of care into our algorithm for the management of
patients with lung cancer."

Thoracic surgery is typically performed by heart surgeons who are already
Novadaq's targeted customers for the SPY Imaging System. Additionally,
thoracic surgeon specialists within the same practice, or specialists at
cancer centers represent a synergistic and significant target market for
PINPOINT. Protected by a significant portfolio of registered patents, PINPOINT
does not require the administration of any contrast agent, but instead
utilizes the fluorescence signal from the naturally occurring fluorophors in
lung tissue to assist doctors in localizing pre-cancerous and cancerous
lesions. It is expected that surgeons and specialists would use these enhanced
imaging capabilities to plan and deliver minimally invasive treatments such
as, PDT or Cryotherapy. A multi-center clinical trial of safety and
effectiveness demonstrated that the use of Novadaq's autofluorescence imaging
technology resulted in a 325% per lesion and a 250% per patient improvement in
the detection of early stage lung cancers compared to conventional white light
bronchoscopy. Another clinical study of 151 patients showed that
autofluorescence was more sensitive than flexible video bronchoscopy (FVB).
Autofluorescence effectively identified 96% or more of lesions of moderate
dysplasia, compared to only 72% with FVB, as referenced in the ACCP

"PINPOINT further deepens our value proposition to the Cardiothoracic
surgical specialty and furthers the agenda for more minimally invasive image
guided surgeries," said Dr. Arun Menawat, President and CEO of Novadaq
Technologies, Inc. "Bronchoscopy is routinely done, but conducting the same
procedure using PINPOINT allows surgeons to capture images that are proven to
be far more clinically relevant and may lead to better patient care and
outcomes including the potential to save lives."

About Novadaq Technologies

Novadaq Technologies Inc. (TSX:NDQ) develops and commercializes medical
imaging systems and real-time image guided therapies for use in the operating
room. Novadaq's proprietary ICG imaging systems can be used to visualize blood
vessels, nerves and the lymphatic system during a variety of surgical
procedures. Novadaq's SPY® Imaging System, commercially available worldwide,
enables cardiac surgeons to visually assess coronary vasculature and bypass
graft functionality during the course of heart bypass surgery. The SPY System
is expandable to include upgrade kits for use during other surgeries such as
plastic, reconstructive and organ transplant surgery allowing surgeons to
evaluate blood flow and tissue and organ perfusion. In addition, SPY is ideal
for use during urological procedures enabling surgeons to visualize vessels,
tumors, the lymphatic system and potentially nerve bundles. Novadaq's OPTTX®
System is aimed at the diagnosis, evaluation and treatment of wet Age-related
Macular Degeneration (AMD) by using the same core imaging technology that is
used in the SPY Imaging System. Novadaq also offers the FDA approved
PINPOINT™ endoscopic system for visualizing native tissue fluorescence
which allows surgeons to differentiate between healthy and cancerous tissue in
the lung during thoracic surgery. Novadaq is also the exclusive United States
distributor of PLC Medical's CO(2) HEART LASER™ System for TMR
(Trans-Myocardial Revascularization). For more information, please visit the
company's website at

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, the
market entry (and timing thereof) of additional suppliers of ICG, market
acceptance and future commitments for the PINPOINT endoscopic imaging system
and other Novadaq devices. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

For further information: visit our website at

Contact Information